NOTCH1 and esophageal squamous cell carcinoma: Subsequent studies confirmed the Notch1 subtype in ESCC patients, suggesting that Notch1 mutation may serve as a predictive biomarker for longer overall survival (OS) with tislelizumab compared to chemotherapy, potentially associated with enrichment of IFN-I signatures and reduced infiltration of B cells and neutrophils [55].